Marketscreener, stock market website
16a882039b.CReJ-sHbaDC4Xps5vNgVz5EKACJOcf9crVdfUGjz27M.WC-wrZO3WgT_LfV66IEimsZfaG8ZOcgk_jksHzu64vVLbee_ircedtk12g
Logo MarketScreener
Back
Logo MarketScreener

Enter your password

Forgot your password ?
Subscribe
  • Markets
    Stocks
    Top Capitalization
    United Kingdom
    North America
    Europe
    Asia
    Middle East
    Sector Research
    Company Calendar
    Equity Analysis
    Most popular
    BANK OF NEW YORK MELLON CORPORATION (THE)
    THE PNC FINANCIAL SERVICES GROUP, INC.
    BATH & BODY WORKS, INC.
    JPMORGAN CHASE & CO.
    DANA INCORPORATED
    AMICUS THERAPEUTICS, INC.
    ACADIA PHARMACEUTICALS INC.
    Indices
    Homepage
    Rankings
    Europe
    America
    Asia
    Africa
    Index Analysis
    Indices News
    FTSE 100
    DAX
    CAC 40
    EURO STOXX 50
    S&P 500
    NASDAQ 100
    TSX COMP
    SHANGHAI COMPOSITE
    Currency / Forex
    Homepage
    Rankings
    Currency Cross Rate
    Currency Converter
    Forex Analysis
    Currencies News
    GBP / USD
    GBP / EUR
    GBP / CHF
    GBP / RUB
    GBP / SEK
    Commodities
    Homepage
    Energy
    Precious metals
    Agriculture
    Industrial Metals
    Livestock and Cattle
    GOLD
    CRUDE OIL (WTI)
    CRUDE OIL (BRENT)
    SILVER
    PLATINUM
    Cryptocurrencies
    Homepage
    Rankings
    Charts
    Analysis
    News
    Logo Crypto <span class='ml-5 txt-link txt-s1'>BITCOINBITCOIN
    Logo Crypto <span class='ml-5 txt-link txt-s1'>ETHEREUMETHEREUM
    Logo Crypto <span class='ml-5 txt-link txt-s1'>BINANCE COINBINANCE COIN
    Logo Crypto <span class='ml-5 txt-link txt-s1'>SOLANASOLANA
    Logo Crypto <span class='ml-5 txt-link txt-s1'>CARDANOCARDANO
    Logo Crypto <span class='ml-5 txt-link txt-s1'>CHAINLINKCHAINLINK
    Interest Rates
    Homepage
    Yield Curve
    Developed Nations
    Emerging Countries
    ETF
    Summary
    Screener
    Analysis
    News
  • News
    All News
    Macroeconomics
    Policy
    Geopolitics
    Technology
    International Trade
    Military conflicts
    Taxation
    Sustainable development
    Legal, Regulation and Crime
    Companies
    Financial Results
    Analyst Recommendations
    Transcripts
    Press releases
    Insider transaction
    Controversies
    Innovations and expansions
    IPOs
    Rumors
    Activism
    Negative surprises
    Positive surprises
    New Contracts
    Indices
    Currency / Forex
    Commodities
    Cryptocurrencies
    ETF
    Interest Rates
    Funds
    Economy
    Sectors
    Most Read News
    Hot News
    Business Insiders
  • Analysis
    All Articles
    Must Read
    Equity Analysis
    Interviews
    Indices
    Currencies
    Commodities
    ETF
    Cryptocurrencies
    Stock Trading Strategies
  • Calendar
    Economic Calendar
    Company Calendar
    Dividend calendar
  • Stock Picks
    All our investments
    Europe
    United States
    Asia, Pacific
  • Portfolios
    European Portfolio
    USA Portfolio
    Asian Portfolio
    Virtual Portfolios
  • Watchlists
    My Watchlists
    Watchlists
    My previous session
    My most visited
    Most popular
    Investment Style
    Homepage
    Momentum stocks
    Monthly dividends
    Dividend Kings
    Yield stocks
    ESG stocks
    Dividend Aristocrats
    Investment Themes
    Homepage
    5G
    Powerful brands
    Artificial Intelligence
    Luxury
    Private Equity
    Millennials
  • Rankings
    Top Movers
    Short-Term Gainers & Losers
    Long-term Gainers & Losers
    Unusual volumes
    New Historical Highs
    New Historical Lows
    Top Fundamentals
    Fundamental Composite
    Sales growth
    Earnings Growth
    Profitability
    Finances
    Rankings Valuation
    Valuation Composite
    Capitalization
    P/E ratio
    Enterprise value
    Yield
    Price to Book (PBR)
    Free Cash Flow (FCF)
    Top Consensus
    Consensus composite
    Analyst Opinion
    Target price
    Opinion Divergences
    Estimates Revisions
    Analyst coverage
    Technical Analysis Rankings
    RSI
    GAPS
    STIM
    Daily Breakouts
    Weekly Breakouts
    Trends
    Volatility
    Top ranking ESG
    ESG MSCI
    Environment
    Social
    Governance
    Islamic Finance
    Paris Agreement
    Pre/Post-market Movers
  • Screeners
    Stocks
    ETF
    Insider transactions
  • Tools
    MarketScreener tools
    Stock Screener
    iPhone app
    Expert tools
    Stock Screener PRO
    Portfolio Creator
    Event Screener
    Dynamic Chart
    Company Calendar
    Economic Calendar
    Currency Converter
  • Our Services
    Our subscriptions
    Our Stock Picks
    Stock Screener
    Thematic Investment Lists
    MarketScreener Portfolios
    European Portfolio
    USA Portfolio
    Asian Portfolio
UK Edition
Subscribe
  • Homepage
  • Markets
    • Stocks
      • Top Capitalization
      • United Kingdom
      • North America
      • Europe
      • Asia
      • Middle East
      • Sector Research
      • Company Calendar
      • Equity Analysis
      • Most popular
      • BANK OF NEW YORK MELLON CORPORATION (THE)
      • THE PNC FINANCIAL SERVICES GROUP, INC.
      • BATH & BODY WORKS, INC.
      • JPMORGAN CHASE & CO.
      • DANA INCORPORATED
      • AMICUS THERAPEUTICS, INC.
      • ACADIA PHARMACEUTICALS INC.
    • Indices
      • Homepage
      • Rankings
      • Europe
      • America
      • Asia
      • Africa
      • Index Analysis
      • Indices News
      • FTSE 100
      • DAX
      • CAC 40
      • EURO STOXX 50
      • S&P 500
      • NASDAQ 100
      • TSX COMP
      • SHANGHAI COMPOSITE
    • Currency / Forex
      • Homepage
      • Rankings
      • Currency Cross Rate
      • Currency Converter
      • Forex Analysis
      • Currencies News
      • GBP / USD
      • GBP / EUR
      • GBP / CHF
      • GBP / RUB
      • GBP / SEK
    • Commodities
      • Homepage
      • Energy
      • Precious metals
      • Agriculture
      • Industrial Metals
      • Livestock and Cattle
      • GOLD
      • CRUDE OIL (WTI)
      • CRUDE OIL (BRENT)
      • SILVER
      • PLATINUM
    • Cryptocurrencies
      • Homepage
      • Rankings
      • Charts
      • Analysis
      • News
      • Logo Crypto <span class='ml-5 txt-link txt-s1'>BITCOINBITCOIN
      • Logo Crypto <span class='ml-5 txt-link txt-s1'>ETHEREUMETHEREUM
      • Logo Crypto <span class='ml-5 txt-link txt-s1'>BINANCE COINBINANCE COIN
      • Logo Crypto <span class='ml-5 txt-link txt-s1'>SOLANASOLANA
      • Logo Crypto <span class='ml-5 txt-link txt-s1'>CARDANOCARDANO
      • Logo Crypto <span class='ml-5 txt-link txt-s1'>CHAINLINKCHAINLINK
    • Interest Rates
      • Homepage
      • Yield Curve
      • Developed Nations
      • Emerging Countries
    • ETF
      • Summary
      • Screener
      • Analysis
      • News
  • News
    • All News
      • Macroeconomics
      • Policy
      • Geopolitics
      • Technology
      • International Trade
      • Military conflicts
      • Taxation
      • Sustainable development
      • Legal, Regulation and Crime
    • Companies
      • Financial Results
      • Analyst Recommendations
      • Transcripts
      • Press releases
      • Insider transaction
      • Controversies
      • Innovations and expansions
      • IPOs
      • Rumors
      • Activism
      • Negative surprises
      • Positive surprises
      • New Contracts
    • Indices
    • Currency / Forex
    • Commodities
    • Cryptocurrencies
    • ETF
    • Interest Rates
    • Funds
    • Economy
    • Sectors
    • Most Read News
    • Hot News
    • Business Insiders
  • Analysis
    • All Articles
    • Must Read
    • Equity Analysis
    • Interviews
    • Indices
    • Currencies
    • Commodities
    • ETF
    • Cryptocurrencies
    • Stock Trading Strategies
  • Calendar
    • Economic Calendar
    • Company Calendar
    • Dividend calendar
  • Stock Picks
    • All our investments
    • Europe
    • United States
    • Asia, Pacific
  • Portfolios
    • European Portfolio
    • USA Portfolio
    • Asian Portfolio
    • Virtual Portfolios
  • Watchlists
    • My Watchlists
      • Watchlists
      • My previous session
      • My most visited
      • Most popular
    • Investment Style
      • Homepage
      • Momentum stocks
      • Monthly dividends
      • Dividend Kings
      • Yield stocks
      • ESG stocks
      • Dividend Aristocrats
    • Investment Themes
      • Homepage
      • 5G
      • Powerful brands
      • Artificial Intelligence
      • Luxury
      • Private Equity
      • Millennials
  • Rankings
    • Top Movers
      • Short-Term Gainers & Losers
      • Long-term Gainers & Losers
      • Unusual volumes
      • New Historical Highs
      • New Historical Lows
    • Top Fundamentals
      • Fundamental Composite
      • Sales growth
      • Earnings Growth
      • Profitability
      • Finances
    • Rankings Valuation
      • Valuation Composite
      • Capitalization
      • P/E ratio
      • Enterprise value
      • Yield
      • Price to Book (PBR)
      • Free Cash Flow (FCF)
    • Top Consensus
      • Consensus composite
      • Analyst Opinion
      • Target price
      • Opinion Divergences
      • Estimates Revisions
      • Analyst coverage
    • Technical Analysis Rankings
      • RSI
      • GAPS
      • STIM
      • Daily Breakouts
      • Weekly Breakouts
      • Trends
      • Volatility
    • Top ranking ESG
      • ESG MSCI
      • Environment
      • Social
      • Governance
      • Islamic Finance
      • Paris Agreement
    • Pre/Post-market Movers
  • Screeners
    • Stocks
    • ETF
    • Insider transactions
  • Tools
    • MarketScreener tools
      • Stock Screener
      • iPhone app
    • Expert tools
      • Stock Screener PRO
      • Portfolio Creator
      • Event Screener
    • Dynamic Chart
    • Company Calendar
    • Economic Calendar
    • Currency Converter
  • Our Services
    • Our subscriptions
    • Our Stock Picks
    • Stock Screener
    • Thematic Investment Lists
    • MarketScreener Portfolios
      • European Portfolio
      • USA Portfolio
      • Asian Portfolio
Switch edition
Stock ERAS ERASCA, INC.
Add to a list

Erasca, Inc.

Stocks

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
21:00:00 08/06/2026 BST
After hours 21:49:02
12.87 USD +7.52% Intraday chart for Erasca, Inc. 12.60 -2.10%
06-04 Erasca Shares Rise After BofA Upgrade MT
06-04 Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says MT
Summary
Quotes
Charts
Technical Analysis Static Chart News Chart Sector Chart Comparison Chart Relative Strength Chart
News
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies
Company
Profile Governance Share ownership Insider transactions Connections
Financials
Analysts' Forecasts Income Statement Balance Sheet Cash flow Financial Ratios Business Segments
Valuation
Consensus
Analysts' Opinion Estimates Revisions
Ratings
Calendar
Sector
Sector performance Sector valuations Sector dividends Financial comparisons Sector ratings Sector consensus Sector revisions
ETFs
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Erasca Teams With Merck on AURORAS-1 Cancer Study

Published on 05/11/2026 at 01:12 pm BST

MT Newswires
Share
LockThis article is reserved for members
Unlock the article: REGISTER NOW!
100% Free Registration
Already a customer? Log In
mtnewswires logo
© MT Newswires - 2026
Share

Latest news about Erasca, Inc.

06-04 Erasca Shares Rise After BofA Upgrade MT
06-04 Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says MT
06-04 BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9 MT
05-14 Erasca, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03:00 PM
05-11 Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-11 Erasca Teams With Merck on AURORAS-1 Cancer Study MT
05-11 Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab) CI
04-28 Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data MT
04-28 Top Premarket Decliners MT
04-28 Erasca shares sink after patient death in early-stage cancer drug trial RE
04-28 Erasca, Inc. - Special Call
04-27 Erasca Inc Announces Positive Preliminary Phase 1 Dose Escalation Data for Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors CI
04-27 Mizuho Raises Price Target on Erasca to $28 From $19, Keeps Outperform Rating MT
04-27 Erasca Inc revolution medicines alleges Erasca's Eras-0015 infringes U.S. patent no. 12,409,225 RE
04-21 Erasca Says Phase 1 Data Readout for ERAS-0015 Expected in May MT

Chart Erasca, Inc.

Chart Erasca, Inc.
ERAS: Dynamic Chart

Company Profile

Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Sector
Biotechnology & Medical Research
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

-
ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
11.97USD
Average target price
21.00USD
Spread / Average Target
+75.44%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
Indices Europe America Asia
My Watchlist
 

My lists
Rankings
 

More Rankings
Rankings
 

More Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

  1. Stock Market
  2. Stock Market News
  3. Erasca Teams With Merck on AURORAS-1 Cancer Study
Best financial portal

Best financial
portal

More than 20 yearsat your side

More than 20 years
at your side

Trustpilot
+ 1,300,000members

+ 1,300,000
members

Quick & easycancellation

Quick & easy
cancellation

Our Expertsare here for you

Our Experts
are here for you

Download from Apple Store

OUR EXPERTS ARE HERE FOR YOU

Monday - Friday 9am-12pm / 2pm-6pm GMT + 1

Contact us
MarketScreener, Stock Market Live
Legal information | Cookie settings | About us | Copyright © 2026 Surperformance SAS. All rights reserved.
Stock quotes are provided by Factset, Morningstar and S&P Capital IQ
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong